Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a strategic collaboration agreement with a Nasdaq listed biopharma company for the development of an optimised oral drug to treat a metabolic condition.
Under the agreement, Poolbeg will receive funding to develop prototype drug using licensed oral delivery technology*. Poolbeg believes that this technology can help to optimise the delivery of its partner’s novel drug to its ideal site of therapeutic action.
Poolbeg is optimistic that this strategic collaboration can progress to a full licensing agreement in time, to allow for the partner company to integrate this novel oral delivery technology into its pipeline.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
